Given the intricacy of the mechanisms underlying the anti-cancer immune response, we assessed immune activation processes and immune infiltration among 33 cancer types and found that NBPF1 may inhibit the activation of anti-tumor immunity, particularly in ACC and SARC. This evidence concerns the gene NBPF1 and neoplasm.